mk-0616
merck
[]
 exclusive #acc23 interview with on the results of a phase 2b clinical trial evaluating mk-0616, an oral macrocyclic #pcsk9 inhibitor. watch now results suggest mk-0616 is safe and effective, with significant #ldl-c reduction! 
📺 Broadcast creators 🎥 Interview makers 👨🏽‍⚕️ CME 📚 Peer-reviewed journal publisher. Content posted intended for HCPs.